Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA1 known ✓ | P02708 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8513720 | 0.95 | GAA (0.48) | GAAMAPTL3MBTL1KDM4ELMNA | |
| Pivalate SCHEMBL9953929 | 0.79 | ALDH1A1 (0.53) | GAAMAPTL3MBTL1KDM4EALDH1A1 | |
| SCHEMBL17201196 | 0.76 | — | — | |
| SCHEMBL17799 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL7501190 | 0.74 | GAA (0.50) | GAAMAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL244807 | 0.74 | GAA (0.50) | GAAMAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL4166547 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL244808 | 0.74 | GAA (0.50) | GAAMAPTL3MBTL1KDM4ELMNA | |
| SCHEMBL2643692 | 0.74 | — | — | |
| SCHEMBL453214 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2026-04-02 | — | — | US | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-04-04 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| US-11623921-B2 | Indole carboxamide compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-04-11 | — | — | US | disclosed |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| EP-3366679-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-20100093756-A1 | HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-04-15 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | PFIZER INC. (US) | 2009-08-20 | — | — | US | disclosed |
| EP-1960391-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | Vernalis (R&D) Limited (GB) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007057687-A1 | PIPERAZINE DERIVATIVES AND THEIR USE IN THERAPY | VERNALIS (R & D) LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
| EP-1786811-A2 | TRIAZOLOPYRIDINE COMPOUNDS | Pharmacia & Upjohn Company LLC (US) | 2007-05-23 | — | — | EP | disclosed |
| EP-1781655-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | Pharmacia & Upjohn Company LLC (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018727-A2 | TRIAZOLOPYRIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006018735-A2 | TRIAZOLOPYRIDINE COMPOUNDS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109874-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRNA1 10/4885GAA 3174/4885MAPT 172/4885 |
| US-20260092052-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM2, CHRM4 | CHRNA1 10/4885GAA 3421/4885MAPT 326/4885 |
| US-20220411413-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRNA1 10/4885GAA 3174/4885MAPT 172/4885 |
| US-20100093756-A1 | HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINE AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA3, ADORA2B | CHRNA1 181/4885GAA 2721/4885MAPT 3383/4885 |
| US-20090209577-A1 | Novel Triazolopyridine Compounds | MAP3K2, MAP3K5, MAP3K9 | CHRNA1 1743/4885GAA 2950/4885MAPT 3005/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CHRNA1 763/4885GAA 4042/4885MAPT 4578/4885 |
| US-20090215817-A1 | Novel Triazolopyridine Compounds for the Treatment of Inflammation | TNF, MAP3K2, MAP3K5 | CHRNA1 1645/4885GAA 3626/4885MAPT 2782/4885 |
| US-11623921-B2 | Indole carboxamide compounds | BTK, JAK2, BRD4 | CHRNA1 763/4885GAA 4042/4885MAPT 4578/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | CHRNA1 763/4885GAA 4042/4885MAPT 4578/4885 |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | CHRNA1 38/4885GAA 3365/4885MAPT 3800/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | CHRNA1 541/4885GAA 3175/4885MAPT 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.